Antibody half-life (days), log2/δAb
|
24 |
22, 26 |
Long-lived cell half-life (yrs), log2/δL
|
6.0 |
2.7, 13 |
Short-lived cell half-life (days), log2/δS
|
|
|
MVA/Ad26 D29 group |
2.0 |
1.3, 3.0 |
MVA/Ad26 D57 group |
4.9 |
3.1, 7.7 |
Ad26/MVA D27 group |
1.2 |
0.8, 1.9 |
Ad26/MVA D57 group |
3.0 |
1.9, 4.7 |
ϕS (ELISA units/ml days−1) |
2,755 |
1,852, 4,100 |
ϕL (ELISA units/ml days−1) |
|
|
East African participants |
16.6 |
13.7, 20.1 |
European participants |
70.7 |
54.0, 92.7 |
σϕS (interindividual SD on ϕS) |
0.92 |
0.83, 1.01 |
σϕL (interindividual SD on ϕL) |
0.85 |
0.78, 0.92 |
σδAb (interindividual SD on δAb) |
0.30 |
0.24, 0.36 |
σAb (SD on observations) |
0.10 |
0.10, 0.10 |